Jung Gil Park

Phase IIa Trial of Locoregional High-Dose Autologous Natural Killer Cell Therapy Combined with Hepatic Arterial Infusion Chemotherapy for Locally Advanced Hepatocellular Carcinoma

PurposeHepatocellular carcinoma (HCC) refractory to locoregional therapies remains a major clinical challenge.This study evaluated the efficacy and safety of locoregional high-dose autologous natural killer (NK) cell therapy combined with hepatic arterial infusion chemotherapy (H...